CROs Running Phase II/III Oncology Trials
Illustrative scenario

Stop Racing the 15-Day SUSAR Clock: AI-Assisted SAE Narrative Drafting for Oncology CROs

For a Global Head of Pharmacovigilance running Phase II/III oncology trials, the math on expedited safety reporting is unforgiving: a 15-day FDA deadline, a 3-to-4-day narrative drafting process, and a team that routinely ships submissions with less than 24 hours to spare. The bottleneck isn't expertise — it's the manual labor of pulling source data from Rave, Argus, and investigator report PDFs before a single sentence gets written.

Up and running in ~10 wkFor: Global Head of Pharmacovigilance
Estimate your payback
~4 mo
Payback period
$9.8M
Est. savings / year
+$6.8M
Year-1 net

Rough estimate — change the numbers to match your business. We scope the real figures with you on a call.

The Real Cost of Manual SAE Workflows

Pharmacovigilance teams at large oncology CROs don't have a writing problem — they have a data aggregation problem. Safety writers spend the bulk of those 3-4 days per case not drafting, but hunting: cross-referencing Medidata Rave audit trails against Oracle Argus Safety case histories, reconciling investigator report PDFs that arrived by email at odd hours, and verifying that every data point in the narrative traces back to a source record. With complex oncology protocols generating high SAE volumes, the cumulative load pushes SUSAR deadlines to the wire. A single missed filing or a narrative that fails FDA ESG submission validation carries regulatory and reputational consequences that dwarf the cost of the workflow itself.

How an AI Agent Handles Case Intake to Draft

An AI Labor Company agent learns the narrative drafting logic embedded in your existing Argus Safety case histories — the structure your medical monitors expect, the phrasing patterns that pass EudraVigilance and FDA ESG validation, the exception handling for incomplete investigator reports. Once deployed, the agent ingests a new SAE at intake: it pulls structured data from Medidata Rave, retrieves the corresponding Argus case record, and parses the investigator report PDF — all within hours of case receipt. It produces a regulation-compliant narrative draft and queues it directly for medical monitor review and E2B submission. Teams in this position typically see case processing compress from 3-4 days to under 12 hours, with 55-75% reduction in the manual labor involved in each case.

The Business Case: Capacity, Not Just Compliance

The clearest value here is risk avoidance — a blown SUSAR deadline or a rejected E2B submission is an organizational event, not a line-item cost. But the growth case matters too. CROs that can handle higher SAE volumes without proportionally scaling pharmacovigilance headcount can take on more trials, more sponsors, and more complex oncology protocols. When safety writers spend their time on medical judgment rather than data extraction, the team's effective throughput expands. The agent is typically live and producing drafts in about 10 weeks from engagement. What that means in practice: the next major enrollment surge doesn't require a hiring decision first.

Works with
Oracle Argus SafetyVeeva Vault SafetyMedidata RaveEudraVigilanceFDA ESG
Questions

Does the agent submit directly to FDA ESG and EudraVigilance, or does it require human sign-off?

The agent drafts and queues — a medical monitor reviews and approves before any regulatory submission. The workflow is designed to compress the time between case intake and a review-ready draft, not to eliminate human oversight from the regulatory filing itself.

How does the agent handle cases with incomplete or late investigator reports?

The agent flags missing data fields rather than fabricating them, and routes incomplete cases to the safety writer with a structured gap list. This actually reduces the time writers spend re-reading the full source record — they receive a targeted exception list instead.

What does the 10-week implementation timeline cover?

It includes extracting narrative logic from your existing Argus case history, configuring the data connections to Rave and Argus Safety, validation against historical cases, and a supervised parallel-run period before the agent handles live cases independently.

Related use cases

Illustrative scenario for healthcare, pharma & life sciences. Figures are example ranges, not guarantees — we scope real numbers with you on a call.

Want this running in your business?

We'll scope an agent for this on a free 15-minute call.

Book a free call